Sab Biotherapeutics Inc (SABS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2017 | 12-2006 | 12-2005 | |
| Assets | ||||
| Current Assets | ||||
| Cash & Cash Equivalents | 12,610 | N/A | N/A | N/A |
| Receivables | 20,570 | N/A | N/A | N/A |
| TOTAL | $34,455 | $N/A | $N/A | $N/A |
| Non-Current Assets | ||||
| PPE Net | 14,846 | N/A | N/A | N/A |
| Other Non-Current Assets | 7,237 | 0 | 0 | 0 |
| TOTAL | $22,083 | $N/A | $N/A | $N/A |
| Total Assets | $56,538 | $N/A | $N/A | $N/A |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts payable and accrued liabilities | 7,382 | 0 | 0 | 0 |
| Accrued Expenses | 1,905 | N/A | N/A | N/A |
| Other current liabilities | 17 | N/A | N/A | N/A |
| TOTAL | $11,062 | $N/A | $N/A | $N/A |
| Non-Current Liabilities | ||||
| Long Term Debt | 172 | N/A | N/A | N/A |
| Deferred Revenues | 100 | N/A | N/A | N/A |
| Other Non-Current Liabilities | 2,373 | 0 | 0 | 0 |
| TOTAL | $6,468 | $N/A | $N/A | $N/A |
| Total Liabilities | $17,530 | $N/A | $N/A | $N/A |
| Shareholders' Equity | ||||
| Common Shares | 3 | N/A | N/A | N/A |
| Retained earnings | -11,984 | N/A | N/A | N/A |
| TOTAL | $39,008 | $N/A | $N/A | $N/A |
| Total Liabilities And Equity | $56,538 | $0 | $0 | $0 |